Ovoca Bio plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OVB.L research report →
Companyovocabio.com
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services.
- CEO
- Timothy Rand McCutcheon
- IPO
- 2000
- Employees
- 5
- HQ
- Dublin, IE
Price Chart
Valuation
- Market Cap
- $2.14M
- P/E
- -0.17
- P/S
- 0.00
- P/B
- 0.32
- EV/EBITDA
- 4.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -92.78%
- ROIC
- -203.88%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-746,000 · 84.13%
- EPS
- $0.00 · 100.00%
- Op Income
- $-3,000
- FCF YoY
- -206.57%
Performance & Tape
- 52W High
- $13.50
- 52W Low
- $3.13
- 50D MA
- $4.51
- 200D MA
- $3.71
- Beta
- 0.91
- Avg Volume
- 75.52K
Get TickerSpark's AI analysis on OVB.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OVB.L Coverage
We haven't published any research on OVB.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OVB.L Report →